[1]
|
Song, Z., Wu, Y., Yang, J., Yang, D. and Fang, X. (2017) Progress in the Treatment of Advanced Gastric Cancer. Tu-mor Biology, 39, Article ID: 1393375038. https://doi.org/10.1177/1010428317714626
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[3]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[4]
|
Chan, W.-L., Yuen, K.-K., Siu, S.W.-K., Lam, K.-O. and Kwong, D.L.-W. (2017) Third-Line Systemic Treatment Versus Best Supportive Care for Advanced/metastatic Gastric Cancer: A System-atic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 116, 68-81. https://doi.org/10.1016/j.critrevonc.2017.05.002
|
[5]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junc-tion, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
|
[6]
|
Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, V.C. and Lordick, F. (2020) Gastric Cancer. Lancet, 396, 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
|
[7]
|
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373, 23-34. https://doi.org/10.1056/NEJMoa1504030
|
[8]
|
Motzer, R.J., Escudier, B., McDermott, D.F., et al. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373, 1803-1813. https://doi.org/10.1056/NEJMoa1510665
|
[9]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774
|
[10]
|
Jin, X., Liu, Z., Yang, D., Yin, K. and Chang, X. (2022) Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 13, Article 948647. https://doi.org/10.3389/fimmu.2022.948647
|
[11]
|
Kono, K., Nakajima, S. and Mimura, K. (2020) Current Status of Immune Checkpoint Inhibitors for Gastric Cancer. Gastric Cancer, 23, 565-578. https://doi.org/10.1007/s10120-020-01090-4
|
[12]
|
Muro, K., Chung, H.C., Shankaran, V., et al. (2016) Pembroli-zumab for Patients with PD-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 17, 717-726.
https://doi.org/10.1016/S1470-2045(16)00175-3
|
[13]
|
Kang, Y.-K., Boku, N., Satoh, T., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory To, or Intolerant Of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Place-bo-Controlled, Phase 3 Trial. Lancet, 390, 2461-2471.
https://doi.org/10.1016/S0140-6736(17)31827-5
|
[14]
|
Janjigian, Y.Y., Kawazoe, A., Yañez, P., et al. (2021) The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer. Nature, 600, 727-730. https://doi.org/10.1038/s41586-021-04161-3
|
[15]
|
Takei, S., Kawazoe, A. and Shitara, K. (2022) The New Era of Immunotherapy in Gastric Cancer. Cancers, 14, Article No. 1054. https://doi.org/10.3390/cancers14041054
|
[16]
|
Wang, Q., Xie, Q., Liu, Y., et al. (2020) Clinical Characteristics and Prognostic Significance of TCGA and ACRG Classification in Gastric Cancer among the Chinese Population. Molecular Medicine Reports, 22, 828-840.
https://doi.org/10.3892/mmr.2020.11183
|
[17]
|
Kim, S.Y., Park, C., Kim, H.J., et al. (2015) Deregulation of Immune Response Genes in Patients with Epstein-Barr Virus-Associated Gastric Cancer and Outcomes. Gastroenterology, 148, 137-147.
https://doi.org/10.1053/j.gastro.2014.09.020
|
[18]
|
The Cancer Genome Atlas Research Network (2014) Compre-hensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 513, 202-209. https://doi.org/10.1038/nature13480
|
[19]
|
Xie, J., Fu, L. and Jin, L. (2021) Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges. Pathology-Research and Practice, 218, Article ID: 153322. https://doi.org/10.1016/j.prp.2020.153322
|
[20]
|
Bagheri, Y., Babaha, F., Falak, R., et al. (2019) IL-10 Induces TGF-β Secretion, TGF-β Receptor II Upregulation, and IgA Secretion in B Cells. European Cytokine Network, 30, 107-113.
|
[21]
|
Wang, M., Busuttil, R.A., Pattison, S., et al. (2016) Immunological Battlefield in Gastric Cancer and Role of Immunotherapies. World Journal of Gastroenterology, 22, 6373-6384. https://doi.org/10.3748/wjg.v22.i28.6373
|
[22]
|
Tran, P.N., Sarkissian, S., Chao, J., and Klempner, S.J. (2017) PD-1 and PD-L1 as Emerging Therapeutic Targets in Gastric Cancer: Current Evidence. Gastrointestinal Cancer: Targets and Therapy, 7, 1-11.
https://doi.org/10.2147/GICTT.S113525
|
[23]
|
Helmy, K.Y., Patel, S.A., Nahas, G.R. and Rameshwar, P. (2013) Cancer Immunotherapy: Accomplishments to Date and Future Promise. Therapeutic Delivery, 4, 1307-1320. https://doi.org/10.4155/tde.13.88
|
[24]
|
Wang, J., Yuan, R., Song, W., et al. (2017) PD-1, PD-L1 (B7-H1) and Tu-mor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology & Oncology, 10, Article No. 34.
https://doi.org/10.1186/s13045-017-0403-5
|
[25]
|
Li, B., Chan, H.L. and Chen, P. (2019) Immune Checkpoint In-hibitors: Basics and Challenges. Current Medicinal Chemistry, 26, 3009-3025. https://doi.org/10.2174/0929867324666170804143706
|
[26]
|
Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients with Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. https://doi.org/10.1200/JCO.2017.76.6212
|
[27]
|
de Guillebon, E., Roussille, P., Frouin, E. and Tougeron D. (2015) Anti Program Death-1/Anti Program Death-Ligand 1 in Digestive Cancers. World Journal of Gastrointestinal Oncology, 7, 95-101. https://doi.org/10.4251/wjgo.v7.i8.95
|
[28]
|
Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Ef-ficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013. https://doi.org/10.1001/jamaoncol.2018.0013
|
[29]
|
Bang, Y.-J., Kang, Y.-K., Catenacci, D.V., et al. (2019) Pem-brolizumab Alone or in Combination with Chemotherapy as First-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Results from the Phase II Nonrandomized KEYNOTE-059 Study. Gastric Cancer, 22, 828-837.
https://doi.org/10.1007/s10120-018-00909-5
|
[30]
|
Davila, M.L., Bouhassira, D.C.G., Park, J.H., et al. (2014) Chi-meric Antigen Receptors for the Adoptive T Cell Therapy of Hematologic Malignancies. International Journal of Hema-tology, 99, 361-371.
https://doi.org/10.1007/s12185-013-1479-5
|
[31]
|
Andre, T., Shiu, K.-K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 383, 2207-2218. https://doi.org/10.1056/NEJMoa2017699
|
[32]
|
Sadelain, M., Rivière, I. and Brentjens, R. (2003) Targeting Tu-mours with Genetically Enhanced T Lymphocytes. Nature Reviews Cancer, 3, 35-45. https://doi.org/10.1038/nrc971
|
[33]
|
Slaney, C.Y., Kershaw, M.H. and Darcy, P.K. (2014) Trafficking of T Cells into Tumors. Cancer Research, 74, 7168-7174.
https://doi.org/10.1158/0008-5472.CAN-14-2458
|
[34]
|
Fournier, C., Martin, F., Zitvogel, L., et al. (2017) Trial Watch: Adoptively Transferred Cells for Anticancer Immunotherapy. Oncoimmunology, 6, e1363139. https://doi.org/10.1080/2162402X.2017.1363139
|
[35]
|
Zhang, H., Ye, Z.-L., Yuan, Z.-G., et al. (2016) New Strat-egies for the Treatment of Solid Tumors with CAR-T Cells. International Journal of Biological Sciences, 12, 718-729. https://doi.org/10.7150/ijbs.14405
|
[36]
|
Vacchelli, E., Martins, I., Eggermont, A., et al. (2012) Trial Watch: Peptide Vaccines in Cancer Therapy. Oncoimmunology, 1, 1557-1576. https://doi.org/10.4161/onci.22428
|
[37]
|
Matsueda, S. and Graham, D.Y. (2014) Immunotherapy in Gastric Cancer. World Journal of Gastroenterology, 20, 1657-1666. https://doi.org/10.3748/wjg.v20.i7.1657
|
[38]
|
Yang, J., Li, Z.H., Zhou, J.J., et al. (2010) Preparation and Antitumor Effects of Nanovaccines with MAGE-3 Peptides in Transplanted Gastric Cancer in Mice. Chinese Journal of Cancer, 29, 359-364.
https://doi.org/10.5732/cjc.009.10541
|
[39]
|
Schwartzentruber, D.J., Lawson, D.H., Richards, J.M., et al. (2011) Gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. New England Journal of Medicine, 364, 2119-2127.
https://doi.org/10.1056/NEJMoa1012863
|
[40]
|
Okada, K., Fujiwara, Y., et al. (2013) Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) Is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer. Annals of Surgical Oncology, 20, 1035-1043. https://doi.org/10.1245/s10434-012-2680-0
|
[41]
|
Higashihara, Y., Kato, J., Nagahara, A., et al. (2014) Phase I Clinical Trial of Peptide Vaccination with URLC10 and VEGFR1 Epitope Peptides in Patients with Advanced Gastric Cancer. International Journal of Oncology, 44, 662-668.
https://doi.org/10.3892/ijo.2013.2242
|
[42]
|
Ishikawa, H., Imano, M., Shiraishi, O., et al. (2014) Phase I Clinical Trial of Vaccination with LY6K-Derived Peptide in Patients with Advanced Gastric Cancer. Gastric Cancer, 17, 173-180. https://doi.org/10.1007/s10120-013-0258-6
|
[43]
|
Masuzawa, T., Fujiwara, Y., Okada, K., et al. (2012) Phase I/II Study of S-1 plus Cisplatin Combined with Peptide Vaccines for Human Vascular Endothelial Growth Factor Receptor 1 and 2 in Patients with Advanced Gastric Cancer. International Journal of Oncology, 41, 1297-1304. https://doi.org/10.3892/ijo.2012.1573
|
[44]
|
Fujiwara, Y., Okada, K., Omori, T., et al. (2017) Multiple Therapeutic Peptide Vaccines for Patients with Advanced Gastric Cancer. International Journal of Oncology, 50, 1655-1662. https://doi.org/10.3892/ijo.2017.3955
|